EP. 2 Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial
EP. 4 Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?
September 20th, 2026Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.Read more
September 10th, 2026Which Lung Cancer Presentations Will Move the Needle at WCLC 2026?Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.Read more
September 9th, 2026OST-HER2 Yields Significant 3-Year Survival in Pulmonary OsteosarcomaThe interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.Read more